Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become available in January, analysts say.
The recent approval of new appetite- and weight-reducing drugs in the United States may lead to significant changes in the packaged food and fast-food industries next year, as increasing use of these medications is shifting consumer dietary preferences.
According to reports, the US Food and Drug Administration (FDA) this week approved Novo Nordisk’s GLP-1 pill, Wegovy. Following the announcement, shares of several food manufacturing companies experienced declines.
Analysts note that the growing popularity of weight-loss drugs is driving consumers toward higher-protein foods, smaller portion sizes, and products with health-related claims.
In response, food companies are already adjusting product labeling, increasing protein content, and offering smaller portion options to align with changing consumer demands.
Research shows that individuals using these drugs reduced grocery spending by an average of 5.3 percent and fast-food restaurant visits by about 8 percent, though these effects tended to decrease after stopping the medication.
The report also highlighted that major companies have already introduced higher-protein and specialized products, while some restaurant chains have added smaller, more affordable menu options.
Experts predict that the easy availability and relatively low cost of these weight-loss pills will likely sustain their long-term use, resulting in lasting shifts in food demand and the types of products offered by the industry.
This development signals a potential long-term transformation in consumer eating habits and the broader food market.
